Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

Commitments and Contingencies - Additional Information (Detail) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Commitment And Contingencies [Line Items]
Gross proceeds from private placement of common stock	$ 3,939,800	$ 11,913,442	$ 13,000,000
Convertible Promissory Note [Member]
Commitment And Contingencies [Line Items]
convertible promissory note issued to pay technology access fee	1,956,000
Maturity date of convertible note	Dec. 31, 2013
MU1140 [Member]
Commitment And Contingencies [Line Items]
License Agreement, Original Date	Jun. 22, 2000
License agreement, first amendment date	Sep. 15, 2000
License agreement, second amendment date	Jul. 10, 2002
License agreement, third amendment date	Sep. 25, 2002
License agreement, fourth amendment date	Mar. 17, 2003
License agreement date fifth amended	Apr. 19, 2013
Patents license expiration period	2017 through 2019
Smart Replacement Therapy [Member]
Commitment And Contingencies [Line Items]
License Agreement, Original Date	Aug. 04, 1998
License agreement, first amendment date	Sep. 15, 2000
License agreement, second amendment date	Jul. 10, 2002
License agreement, third amendment date	Sep. 25, 2002
License agreement, fourth amendment date	Mar. 17, 2003
License agreement date fifth amended	Apr. 19, 2013
Patent right filling date	Jun. 07, 1995
Patent effective date	Mar. 04, 1997
Patent right expire date	Jun. 07, 2015
UFRF License Agreements [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product	5.00%
Company's obligation to pay from all revenue received from sublicenses	22.00%
One-time commercialization fee would be due on the first anniversary of first commercial sale	5,000
Post-commercialization minimum royalty payments	50,000
One-time additional royalty payment would be due when total cumulative royalties	2,000,000
Total royalties due to UFRF	10.00%
Minimum annual maintenance payment per license agreement	10,000
Aggregate minimum annual maintenance payment	20,000
Quarterly maintenance payment to UFRF under installment plan	5,000
Lantibiotic ECC [Member]
Commitment And Contingencies [Line Items]
License Agreement, Original Date	Jun. 05, 2012
Termination notice period	90 days
Common stock issued	4,392,425
Percentage company pay on quarterly basis out of gross profit	25.00%
Company's obligation to make payment from all revenue received from sublicensing	50.00%
Period during which company cannot terminate license agreement voluntarily	18 months
Period during which company cannot terminate license agreement	12 months
Maximum percentage of primary investment securities to investment of shares issued	10.00%
Lantibiotic ECC [Member] \| Investigational New Drug Application [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	1.00%
Lantibiotic ECC [Member] \| Clinical Study Phase 2 [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	1.50%
Lantibiotic ECC [Member] \| Clinical Study Phase 3 [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	2.00%
Lantibiotic ECC [Member] \| Filing of First Investigational New Drug Application [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	2.50%
Lantibiotic ECC [Member] \| First Regulatory Approval of Oragenics Product [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	3.00%
Probiotics ECC [Member]
Commitment And Contingencies [Line Items]
License Agreement, Original Date	Sep. 30, 2013
Percent of company pay out of net sales	10.00%
Termination notice period	90 days
Maximum period to cure the breach	60 days
Up-front technology access fee	6,000,000
Milestone amount payable one	2,000,000
Milestone amount payable two	5,000,000
Milestone amount payable three	10,000,000
Milestone measurement period	30 days
Probiotics ECC [Member] \| Intrexon [Member]
Commitment And Contingencies [Line Items]
Common stock issued	1,348,000
Company's common stock shares sold	1,300,000
Per shares price	$ 3.00
Gross proceeds from private placement of common stock	3,900,000
Probiotics ECC [Member] \| Convertible Promissory Note [Member]
Commitment And Contingencies [Line Items]
convertible promissory note issued to pay technology access fee	$ 1,956,000
Maturity date of convertible note	Dec. 31, 2013